Cyfuse Biomedical KK
TSE:4892
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (8.1), the stock would be worth ¥663.42 (2% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.3 | ¥678 |
0%
|
| 3-Year Average | 8.1 | ¥663.42 |
-2%
|
| 5-Year Average | 8.4 | ¥685.54 |
+1%
|
| Industry Average | 1 | ¥83.56 |
-88%
|
| Country Average | 1 | ¥78.41 |
-88%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
C
|
Cyfuse Biomedical KK
TSE:4892
|
6.5B JPY | 8.3 | -8.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 84.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.4B USD | 1.9 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
124B USD | 1.8 | 33.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 5.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 2 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.4B USD | 3.2 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.1B USD | 7 | 46.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.8B USD | 1.6 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.8B USD | 8.2 | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 1 |
| 70th Percentile | 1.5 |
| Max | 23 050 349 |
Other Multiples
Cyfuse Biomedical KK
Glance View
Cyfuse Biomedical KK develops and manufactures cell regenerative systems. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2022-12-01. The firm is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The firm is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The firm is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.
